Guillain-Barré syndrome: COVID-19 as a possible trigger

Guillain-Barré syndrome (GBS) has so far emerged as a possible vaccination consequence of the vector vaccines against COVID-19. But the autoimmune reaction is also possible after a COVID-19 disease.

Guillain-Barré syndrome is a very rare neurological disease, with only around 3,000 to 6,000 cases being registered in the USA each year.

Guillain-Barré Syndrome: Signs

Guillain-Barré syndrome is acute or subacute inflammation. GBS usually occurs in the area of ​​the spinal cord and particularly affects the peripheral nerves. The syndrome could be triggered by an immune reaction against certain viruses or bacteria. Some of these antibodies could also attack parts of the nerve fibers and cause GBS.

Common symptoms of Guillain-Barré syndrome are:

  • numbness
  • Sudden weakness
  • Local pains in the extremities
  • pins and needles, tingling or tingling in your arms and legs

Experts assume that this immune reaction can also occur after a corona infection.

Guillain-Barré syndrome after corona infections

Scientists from the Erasmus University in Rotterdam noted eleven previous COVID-19 diseases in 49 cases of GBS. In Italy, too, which had many corona cases and high incidences, especially at the beginning of the  pandemic  , patients with GBS were increasingly registered.

In medicine, it is also assumed that people who have had  SARS-CoV-2  are six times more likely to develop GBS than others. However, due to the small number of diseases, causality has not yet been established.

As with other diseases, the number of GBS cases has decreased overall during the pandemic, presumably also because fewer infections with other viruses and bacteria have occurred overall.

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *